In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia
THE POWER TO
PREVENT RISING URIC
ACID LEVELS IS IN YOUR
HANDS
In patients at risk of tumor lysis syndrome (TLS) associated with hyperuricemia
THE POWER TO PREVENT RISING URIC ACID LEVELS IS IN YOUR HANDS
In a phase 3 trial, ELITEK given prophylactically (prior to anticancer therapy) maintained normal uric acid levels (≤7.5 mg/dL) in significantly more patients (87%, n=92) vs allopurinol (66%, n=91) between 3 and 7 days after initiation of antihyperuricemic treatment (P=0.001) (primary endpoint).1
Mechanism of Action
See how ELITEK functions differently than allopurinol
Identify Patients at Risk
Know what to look for in your patients
Reference: 1. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213.